ArticleFrontiers in medicine2026
Case Report: A rare motor storm in lupus: opsoclonus-myoclonus-ataxia syndrome as an atypical presentation of severe systemic lupus erythematosus.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare hyperkinetic movement disorder characterized by opsoclonus, generalized myoclonus, and cerebellar ataxia. In adults, OMAS is most often reported in paraneoplastic or postinfectious settings, whereas autoimmune etiologies are less common. Case presentation: A 21-year-old woman with a 7-month history of SLE developed a 3-week subacute OMAS phenotype with opsoclonus, generalized myoclonus, and gait/limb ataxia, leading to loss of independent ambulation. CSF, microbiological testing, and brain MRI were unremarkable, and initial malignancy screening was negative. Severe lupus activity was documented (SLEDAI-2 K 27). She received methylprednisolone pulses, plasmapheresis, and rituximab, with progressive neurological recovery and a decrease in lupus activity to SLEDAI-2 K 4. At discharge, she ambulated independently with mild residual gait ataxia. Conclusion: This case expands the spectrum of neuropsychiatric SLE by illustrating OMAS as a predominantly motor phenotype. A structured evaluation to exclude structural, infectious, and malignant etiologies is essential, and early escalation of immunotherapy may be associated with substantial neurological recovery when OMAS occurs in the context of severe lupus activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.